Application
MLM Antibody (C-term) western blot analysis in 293 cell line lysates (35ug/lane).This demonstrates the MLM antibody detected the MLM protein (arrow).Application
MLM Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human pancreas tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of MLM Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.Application
MLM Antibody (C-term) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Product Name | MLM Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | CDKN2A; CDKN2; MLM; Cyclin-dependent kinase inhibitor 2A, isoform 4; p14ARF; p19ARF |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHCFC |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | CDKN2 MLM |
|---|---|
| Alternative Names | CDKN2A CDKN2 MLM Cyclin-dependent kinase inhibitor 2A isoform 4 p14ARF p19ARF |
| Molecular Weight(MW) | 13903 Da |
| Function | Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus This inhibits the oncogenic action of MDM2 by blocking MDM2- induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform 6 may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP |
| Tissue Specificity | This MLM antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 112-141 amino acids from the C-terminal region of human MLM. |
| Cellular Localization | Nucleus, nucleolus. Nucleus, nucleoplasm. |
| Entrez Gene | 1029 |
|---|---|
| Nucleotide Accession | NP_478102.2 |
Application
MLM Antibody (C-term) western blot analysis in 293 cell line lysates (35ug/lane).This demonstrates the MLM antibody detected the MLM protein (arrow).
Application
MLM Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human pancreas tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of MLM Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Application
MLM Antibody (C-term) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
